Healthcare Innovation

Pierre Fabre Resubmits FDA BLA for Tabelecleucel in Rare Post-Transplant Cancer

Secaucus, N.J. – September 30, 2026 -- Pierre Fabre Pharmaceuticals Inc. (PFP) has resubmitted a Biologics License Application to the U.S. Food and Drug Administration for tabelecleucel, seeking approval as a monotherapy for adult and pediatric patients aged 2 and older with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed at least one prior therapy.

Resubmission follows April 2026 FDA alignment meeting

PFP filed the updated application after reaching agreement with the FDA during an April 2026 Type A meeting. The package includes an expanded dataset with additional patients and longer follow-up from the pivotal Phase 3 ALLELE study, which evaluates tabelecleucel in patients with EBV+ PTLD following hematopoietic cell transplant (HCT) or solid organ transplant (SOT).

Novo Nordisk: Wegovy Pill Switch Study Shows 8.8 lb Loss in 3 Months

Plainsboro, New Jersey – – September 30, 2026 -- Adults with overweight or obesity who switched from injectable GLP-1 therapies to the oral Wegovy pill lost an average of 4.0 kg (8.8 lb) over three months, according to new real-world data from Novo Nordisk's OCTANE study presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes in Milan on September 30, 2026.

Patients switching to the oral formulation saw rapid weight-loss gains after three months

The retrospective analysis of 194 patients on the Ro telehealth platform found that 40.7% achieved weight loss of 5% or more within three months of switching from injectable semaglutide or tirzepatide to once-daily oral semaglutide (p0.001). The proportion of participants classified with a BMI of 30 kg/m2 or higher fell by 21.6 percentage points, dropping from 87.1% at baseline to 65.5% at the three-month mark.

EQT Foundation Funds €1M for 11 Brain Drug-Delivery Projects

Stockholm – – September 30, 2026 -- EQT Foundation has committed more than EUR 1 million to 11 research projects across 10 institutions aimed at solving one of neuroscience's most persistent commercial barriers: getting therapeutics past the blood-brain barrier and into the central nervous system.

Eleven projects target the blood-brain barrier from different scientific angles

The funded research spans engineered biological carriers, molecular shuttles, gene therapy vectors, nanoparticles and AI-designed delivery technologies. Institutions involved are located in the Netherlands, Belgium, the United States and Canada, with initial disease applications including brain cancer, ALS and rare genetic disorders.

Roche Unit Launches Triple Newborn Screening Test for SMA, SCID, SCD

Berlin – – September 30, 2026 -- TIB MOLBIOL, a subsidiary of Roche Diagnostics, has launched the LightMix® Newborn TREC/SMN1/HBB kit, an IVDR-approved in vitro diagnostic test that simultaneously screens newborns for Spinal Muscular Atrophy (SMA), Severe Combined Immunodeficiency Disease (SCID), and Sickle Cell Disease (SCD) in countries accepting the CE mark.

Single kit consolidates three critical newborn screening panels for hospital labs

The test runs on established LightCycler systems, giving private and academic hospital laboratories a ready-to-use solution that integrates into existing workflows without requiring new infrastructure investment.

Dimora Medical Launches MegaSorb Foam Dressing for Elderly Wound Care

New York – – September 29, 2026 -- Dimora Medical unveiled a silicone foam wound dressing built on its MegaSorbTM Dual-Action Absorption System, targeting moderate to heavy exudate wounds common among elderly patients with pressure ulcers and chronic wounds. The launch coincides with the 2026 United Nations International Day of Older Persons, observed under the theme "The Age of Longevity: Rethinking Systems for Longer Lives."

MegaSorb foam absorbs up to 15 times its own weight in wound exudate

The dressing uses a high-porosity polymer with an open-cell structure reaching up to 90%, enabling it to lock in exudate within one second and reduce leakage and backflow risk. Dimora Medical positions the technology as a direct response to gaps in traditional wound dressings, which frequently fail to manage moderate to heavy exudate, causing maceration of surrounding skin and painful dressing changes.

Thyme Companies Names Flatiron Health Ex-CEO Starrett to Lead New Ventures

Nashville, Tenn. – – September 29, 2026 -- Thyme Companies has appointed Carolyn Starrett as executive vice president of new ventures, tasking her with identifying and scaling new businesses beyond its existing Thyme Care platform. Starrett reports directly to Executive Chairman Robin Shah, marking her second collaboration with him after their tenure together at Flatiron Health.

Starrett brings a decade of oncology data leadership from Flatiron Health

Starrett joined Flatiron Health in 2016 alongside Thyme's founders and served as its Chief Executive Officer from 2021 to 2025. Under her leadership, Flatiron's real-world evidence platform expanded from roughly 400,000 to more than 5.5 million patient records. Its OncoEMR platform grew to serve more than 4,500 oncology providers nationwide, while the company extended research operations into the United Kingdom, Germany and Japan.

Autoimmune Treatment Market to Nearly Double to $321.95B by 2034

Pune – September 25, 2026 -- The global autoimmune treatment market reached USD 176.6 billion in 2025 and is forecast to expand at a 6.9% CAGR through 2034, hitting USD 321.95 billion, according to a new analysis from Maximize Market Research.

North America dominates the market on strong pharmaceutical R&D infrastructure

North America held the largest share of the market in 2025, driven by high disease prevalence, advanced healthcare infrastructure, established specialist care and elevated healthcare spending. The United States anchors regional growth, backed by leading pharmaceutical and biotechnology firms, advanced diagnostic capacity, and rising adoption of biologics, immunosuppressants, monoclonal antibodies and targeted therapies. Canada and Mexico are contributing through improving healthcare access and disease awareness.

Clarius Repeats on TIME's Top 500 Global HealthTech List

Vancouver – September 25, 2026 -- Clarius Mobile Health has been named to TIME's list of the World's Top HealthTech Companies 2026 for the second consecutive year, placing it among just 500 companies selected from thousands reviewed globally.

TIME and Statista ranked Clarius on financial performance, reputation and online engagement

The list, presented by TIME and Statista Inc., was announced on September 25, 2026. Statista evaluated thousands of HealthTech companies worldwide before narrowing the field to the top 500 recognized for their performance across financial, reputational and engagement metrics.

BPD Health Rebrands, Positions Itself as Healthcare Growth Partner

Boca Raton, Fla. – September 24, 2026 -- BPD Health has launched a new brand identity, "It's Good to Grow," repositioning the two-decade-old healthcare marketing firm as a strategic growth partner for hospitals, life sciences firms and health innovators.

BPD traces its evolution from an advertising agency to a growth strategy firm

The company has operated under three names over more than 20 years: BPD Advertising, BPD Healthcare, and now BPD Health. Each iteration marked an expansion of scope, moving from healthcare marketing services toward broader strategic growth advisory work for health systems, life sciences companies, healthcare associations and consumer health brands.

Ping An Good Doctor Links AI to Human Care Networks in China

Hong Kong – September 24, 2026 -- Ping An Good Doctor (HKEX: 1833) said its AI business accounted for approximately 4.6% of gross profit in the first half of 2026, as the Hong Kong-listed insurer's healthcare arm shifts from diagnostic AI tools toward services that execute care plans on the ground.

Ping An launches AI-powered home rehab coaching

The company upgraded its Ping An AI Doctor service with Ping An Smart Private Coach, a hybrid AI-and-coaching offering that tracks 34 points on the body to deliver real-time feedback across seven categories, including posture correction, chronic-pain rehabilitation, postpartum recovery and Baduanjin qigong exercise. The global market for AI personal trainers is projected to grow from $16.9 billion in 2025 to $65.7 billion by 2033, a trend coinciding with China's National Health Commission "Weight Management Year" initiative launched in 2024.